Q1 2017 Holdings
Filed 2017-05-15 | 23 holdings | $164.7M | 13F-HR | View on SEC ↗ · Holdings Table ↗
Sign in to see sub-manager breakdown
| Issuer | Class | CUSIP | Value ↓ | Shares | % Portfolio |
|---|---|---|---|---|---|
| Aclaris therapeutics(ACRS) | Common | 00461U105 | $85.2M | 2,858,569 | 51.8% |
| Ascendis Pharma(ASND) | ADR | 04351P101 | $49.5M | 1,766,832 | 30.0% |
| Codexis, Inc.(CDXS) | Common | 192005106 | $25.4M | 5,294,825 | 15.4% |
| Aurinia Pharmaceuticals Inc.(AUPH) | Common | 05156V102 | $4.4M | 600,000 | 2.7% |
| Nabriva Therapeutics AG | ADR | 62957M104 | $48.3K | 4,021,559 | 0.0% |
| Eiger BioPharmaceuticals(CLDNEUR) | Common | 28249U105 | $20.5K | 1,787,091 | 0.0% |
| Advanced Accelerator Applications S.A. | Sponsored ADS | 00790T100 | $19.3K | 483,786 | 0.0% |
| Aimmune Therapeutics, Inc.(AIMT) | Common | 00900T107 | $16.6K | 763,009 | 0.0% |
| Strongbridge Biopharma plc | Ordinary Shares | G85347105 | $14.3K | 3,000,000 | 0.0% |
| Capnia, Inc. | Common | 14066L105 | $10.4K | 14,695,264 | 0.0% |
| BioPharmX Corporation | Common | 09072X101 | $6.5K | 12,814,286 | 0.0% |
| Trevena, Inc. | Common | 89532E109 | $6.3K | 1,728,000 | 0.0% |
| Akari Therapeutics Plc | ADR | 00972G108 | $5.8K | 527,842 | 0.0% |
| Agile Therapeutics, Inc.(AGRXUSD) | Common | 00847L100 | $4.9K | 1,513,975 | 0.0% |
| Foamix Pharmaceuticals Ltd. | Common | M46135105 | $4.2K | 855,000 | 0.0% |
| Sierra Oncology Inc. | Common | 82640U107 | $3.7K | 2,438,270 | 0.0% |
| Crispr Therapeutics AG(CRSP) | Namen AKT | H17182108 | $3.2K | 148,878 | 0.0% |
| Regenxbio Inc.(RGNX) | Common | 75901B107 | $3.2K | 164,403 | 0.0% |
| KalVista Pharmaceuticals, Inc.(KALV) | Common | 483497103 | $2.3K | 300,325 | 0.0% |
| Dynavax Technologies Corporation(DVAX) | Common | 268158201 | $2.1K | 359,828 | 0.0% |
| Sunesis Pharmaceuticals, Inc. | Common | 867328700 | $2.1K | 500,000 | 0.0% |
| ReVance Therapeutics, Inc.(RVNCEUR) | Common | 761330109 | $1.6K | 77,373 | 0.0% |
| Capnia, Inc. | Warrant | 14066L113 | $113 | 943,858 | 0.0% |